The company MUST outline how secondary patents can be (and are...

The company MUST outline how secondary patents can be (and are being) used to delay or prevent generic competition upon expiry of their basic patents (especially in regards to wedge-sealing).

Patents and associated intellectual property are the life-blood of MST at this stage, seeing as productization efforts have led nowhere, therefore the company MUST communicate the I.P. management plan in more detail to shareholders; it is unacceptable that the company dismissively states that particular patents will not be missed, especially when in the past they have outlined the commercial potential of such patents as mentioned by Routine.